12 results about "Iodized oil" patented technology

The invention relates to the technical field of radiotherapy auxiliary instruments, in particular to an injectable calcium sodium alginate hydrogel spacer for radiotherapy and a preparation method of the injectable calcium sodium alginate hydrogel spacer. Nano calcium carbonate is used as an adjusting switch, an adjustable mechanical and degradation performance foundation of the hydrogel is laid, and the material is endowed with unique bifunctional characteristics through the synergistic effect of the nano calcium carbonate, a contrast agent iodized oil and a degradation liquid diethylenetriamine pentaacetic acid. The hydrogel can quickly form gel after being injected, keeps long-term structural stability and clear CT imaging capability in vivo, and can monitor the position and form of the hydrogel in a lossless manner; and when the radiotherapy period is finished, the on-demand and rapid degradation of the hydrogel can be realized only by injecting the diethylenetriamine pentaacetic acid, so that the risk of long-term retention is avoided. In-vitro and in-vivo experiments prove that the material has good biocompatibility, can significantly reduce the radiation dose of normal tissues such as rectum and the like, realizes the technical span from invisibility and difficult degradation to visibility and degradability, and has great clinical transformation value.

The application discloses a polymer vesicle-stabilized drug-iodized oil emulsion and a preparation method and application thereof, to realize safe and efficient transarterial chemoembolization (TACE) treatment of hepatocellular carcinoma in situ. The drug-iodized oil emulsion system has the following advantages: simple preparation, convenient size adjustment, excellent stability, near-zero order and sustained controllable drug release rate, low blood drug concentration after transarterial embolization, and the retention time and retention amount of the drug in the liver are superior to those of free drug-iodized oil emulsion used in clinical treatment, the tumor can be completely eradicated, angiogenesis can be effectively inhibited, and adverse reactions can be reduced. In general, the polymer vesicle-stabilized drug-iodized oil emulsion has the advantages of high stability and sustained controllable drug release, and can greatly improve the embolization chemotherapy effect of hepatocellular carcinoma, and provide a safe and efficient TACE strategy.

The application discloses a stable liver cancer embolism emulsion of raltitrexed drug gel and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The emulsion is composed of iodized oil embolism agent and raltitrexed drug gel; the raltitrexed drug gel is a nanofiber network hydrogel formed by self-assembly of raltitrexed molecules in an aqueous phase through ultrasonic treatment, and simultaneously serves as an active pharmaceutical ingredient and an emulsion stabilizer. The iodized oil and the raltitrexed drug gel are physically mixed and injected through a three-way valve to form a stable oil-in-water emulsion or a water-in-oil emulsion, and any additional chemical surfactant or cosolvent is not needed. The emulsion has excellent physical stability, and can effectively solve the problems of easy aggregation and sedimentation of a traditional iodized oil emulsion and increased systemic toxicity caused by drug burst release. The emulsion has good embolism effect and drug release behavior, can significantly inhibit tumor growth, and has a wide clinical transformation prospect.

1. The name of the design product: medical iodine oil and glue mixer. 2. The use of the design product: for mixing iodine oil with gelatin particles and other embolization materials. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

The utility model relates to the field of medicine emulsifying devices, in particular to a micro-fluidic emulsifying unit for iodophol and chemotherapeutics, which comprises a micro-channel reaction module and an electronic tag, a micro-channel for emulsifying chemotherapeutics and iodophol is arranged in the micro-channel reaction module, and the electronic tag is arranged in the micro-channel reaction module. Three Luer tapers connected with the micro-channel are arranged outside the micro-channel reaction module, and the electronic tag is installed on the surface of the micro-channel reaction module and used for storing emulsion configuration information. According to the embodiment of the utility model, a doctor can select the micro-channel reaction module with a proper model according to the diameter of a tumor blood supply artery and confirm the model of the micro-channel reaction module by scanning the electronic tag, so that the emulsion with the droplet size meeting the requirement is formed.

The invention discloses a pharmaceutical composition for tumor embolism treatment. The pharmaceutical composition consists of a tirapazamine derivative RTPZ and iodophol. The preparation method comprises the following steps: S1, dissolving tirapazamine and an alkaline substance in a solvent, and adding alkyl acyl chloride for reaction until the raw materials are completely converted; s2, after the reaction in the S1 is finished, performing rotary evaporation to remove the solvent, adding dichloromethane for dissolving, washing with a saturated saline solution, drying with anhydrous sodium sulfate, and finally evaporating to remove the solvent to obtain a crude product; s3, purifying the crude product to obtain RTPZ; and S4, directly dissolving the RTPZ in the iodinated oil until the RTPZ is saturated. According to the invention, the characteristics of a high oil-soluble drug, an iodized oil embolism agent and slow release are integrated, a local, slow-release and target hypoxic tumor treatment system for transcatheter arterial chemoembolization is constructed, an anti-tumor effect far better than that of a raw drug TPZ is achieved on a VX2 rabbit tumor embolism model, and a microenvironment after embolism can be effectively regulated and controlled.

The invention provides a novel iodinated polyunsaturated fatty acid ethyl ester compound as well as a preparation method and application thereof, and DHA or EPA is used as a raw material for esterification reaction to prepare iodinated DHA ethyl ester and iodinated EPA ethyl ester. Compared with the existing iodinated oil, the iodinated polyunsaturated fatty acid ethyl ester has higher iodine content range, lower drug dosage and better stability.

The invention discloses a treatment method for intractable pneumothorax under the guidance of CT (Computed Tomography), which comprises the following steps of: 1, carrying out clinical examination before an operation on an intractable pneumothorax patient needing to be treated through clinical consultation, carrying out consultation judgment according to the clinical examination, and signing an informed consent before the operation; the position and the form of the broncho pleural fistulae are accurately displayed through CT three-dimensional reconstruction, the position of the fistulae is accurately punctured through a PTCB needle under local anesthesia, the purpose of plugging the fistulae is achieved by selecting proper plugging materials such as a medical adhesive / iodized oil mixture, a spring ring and gelatin sponge, and the clinical applicability of the intractable pneumothorax plugging operation under CT guidance is high; required CT and plugging materials are conventionally available in primary hospitals; the device is simple in structure, convenient to operate, accurate in plugging and capable of being carried out only under local anesthesia, most patients can tolerate multiple operations, minimally invasive, safe, efficient and instant in effect, has very important diagnosis and treatment significance on treatment of most refractory pneumothorax, and is worthy of clinical application and popularization.

This invention relates to the field of tumor treatment technology, and particularly to a radioembolization microsphere, a radioembolization microsphere formulation, its preparation method, and its application. The radioembolization microsphere provided by this invention comprises radioactive particles and an organic phase containing iodized oil. The radioactive particles are coated on an interface with the organic phase containing iodized oil as its core. The radioactive particles comprise a radionuclide and an inorganic matrix, with the radionuclide immobilized in the inorganic matrix. The particle size of the radioactive particles is 0.01~10 μm; the particle size of the radioembolization microspheres is 0.01~1000 μm. Applying the radioembolization microspheres of this invention to embolization therapy can maintain long-term retention at the tumor site and reduce radiation damage to non-tumor sites. The iodine component provides X-ray imaging functionality, enabling integrated diagnosis and treatment, radioactive dose tracking, and accurate measurement of radiation dose.

The invention relates to the technical field of biomedical materials, in particular to iodinated oil emulsion gel with a slow release function and a preparation method of the iodinated oil emulsion gel. The invention provides iodinated oil emulsion gel with a slow release function, the iodinated oil emulsion gel comprises an oil phase, a water phase and magnetic response amphiphilic particles, the oil phase is prepared by compounding oleic acid modified magnetic nanoparticles and iodinated oil; the water phase is prepared by dissolving a medicine in deionized water; the magnetic response amphiphilic particles are prepared by carrying out amination modification treatment on magnetic nanoparticles. The preparation method comprises the following steps: preparing oleic acid modified magnetic nanoparticles, compounding the oleic acid modified magnetic nanoparticles with iodinated oil to obtain magnetic iodinated oil, synthesizing magnetic response amphiphilic particles through multiple steps, and matching the magnetic response amphiphilic particles with a drug-containing aqueous phase and a gel agent to successfully prepare iodinated oil emulsion gel with a slow release function, and the iodinated oil emulsion gel has good centrifugal stability.

The invention provides a temperature response type magnetic emulsion embolization agent containing triptolide as well as a preparation method and application of the temperature response type magnetic emulsion embolization agent, and belongs to the technical field of biological medicines. The triptolide temperature response type magnetic emulsion embolization agent comprises triptolide, a temperature-sensitive polymer, iodized oil and magnetic nanoparticles, and the temperature-sensitive polymer can be subjected to phase change at 32 DEG C or above to be gelated. The triptolide temperature response type magnetic emulsion embolism agent provided by the invention can continuously release triptolide and has excellent mechanical properties to realize long-acting tumor vascular embolism, and the magnetic nanoparticles can effectively exert magnetocaloric properties to realize an anti-tumor effect; the iodinated oil has X-ray opaqueness and can be visualized in an embolism operation, the safety in the using process is improved, and then the triple synergistic anti-tumor effect of embolism, chemotherapy and magnetic hyperthermia is achieved.